MorphoSys AG receives final US antitrust clearance for its acquisition by Novartis AG at €68.00 per share.
MorphoSys AG announces receipt of US antitrust clearance under Hart-Scott-Rodino Act for its proposed acquisition by Novartis AG. The approval follows clearances in Germany and Austria, making it the final mandatory regulatory approval needed. Novartis aims to submit a voluntary public takeover offer for all outstanding MorphoSys shares at €68.00 per share in cash, representing a total equity value of €2.7 billion.
March 22, 2024
6 Articles